Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 19/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 17/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 7/20 | 0.80 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.80 |
| ▸ | DRD2 | P14416 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6582012 | 0.89 | ADRA1B (1.00) | HTR1AADRA1BADRA1AADRA1D | |
| SCHEMBL6580070 | 0.89 | HTR1A (1.00) | HTR1AADRA1BADRA1AADRA1DDRD2 | |
| SCHEMBL6582852 | 0.88 | ADRA1B (1.00) | HTR1AADRA1BADRA1AADRA1D | |
| SCHEMBL6577718 | 0.88 | ADRA1B (1.00) | HTR1AADRA1BADRA1AADRA1D | |
| SCHEMBL6579820 | 0.87 | HTR1A (0.80) | HTR1AADRA1BADRA1AADRA1D | |
| SCHEMBL6577740 | 0.86 | ADRA1B (1.00) | HTR1AADRA1BADRA1AADRA1D | |
| SCHEMBL7507581 | 0.85 | ADRA1B (0.73) | HTR1AADRA1BADRA1AADRA1D | |
| SCHEMBL6580037 | 0.84 | HTR1A (1.00) | HTR1AADRA1BADRA1AADRA1DDRD2 | |
| SCHEMBL6580540 | 0.82 | HTR1A (1.00) | HTR1AADRA1BADRA1AADRA1D | |
| SCHEMBL6579957 | 0.80 | HTR1A (1.00) | HTR1AADRA1BADRA1AADRA1DDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1200406-B1 | CYCLIC AMIDES AND IMIDES HAVING SELECTIVE ANTAGONIST ACTIVITY AT ALPHA-1D ADRENERGIC RECEPTOR | RECORDATI CHEM PHARM (IT) | 2004-11-24 | — | — | EP | claimed |
| US-20040106623-A1 | Compounds specific for the human alpha1d adrenergic receptor and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-06-03 | — | — | US | disclosed |
| US-6706716-B2 | NERVOUS SYSTEM DISORDERS; HYPOTENSIVE AGENTS; INCONTINENCE | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-03-16 | — | — | US | disclosed |
| US-20020028760-A1 | Compounds specific for the human alpha1d adrenergic receptor and uses thereof | H. LUNDBECK A/S (DK) | 2002-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106623-A1 | Compounds specific for the human alpha1d adrenergic receptor and uses thereof | ADRA1D, ADRA1A, ADRB1 | HTR1A 27/4885ADRA1B 4/4885ADRA1A 2/4885 |
| US-20020028760-A1 | Compounds specific for the human alpha1d adrenergic receptor and uses thereof | ADRA1D, ADRA1A, ADRB1 | HTR1A 67/4885ADRA1B 4/4885ADRA1A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.